PharmaEssentia Announces Appointment of Meredith Manning to President of the Americas

PharmaEssentia Japan Files Marketing Authorization Application for Ropeginterferon Alfa-2b For the Treatment of Polycythemia Vera

NCCN Clinical Practice Guidelines in Oncology Update Recommends BESREMi(R) (ropeginterferon alfa-2b-njft) for the Treatment of Polycythemia Vera

PharmaEssentia Expands U.S. Leadership with Anjana Pursnani, Head of People, and Jason Mitch, Head of Market Access

PharmaEssentia’s BESREMi (Ropeginterferon alfa-2b-njft) Now Available For the Treatment of People with PV in the United States

U.S. FDA Approves BESREMi(R) (ropeginterferon alfa-2b-njft) As the Only Interferon for Adults with Polycythemia Vera

PharmaEssentia Announces Pipeline Presentation During Upcoming American Society of Hematology Annual Meeting

PharmaEssentia Receives Regulatory Approval in South Korea for BESREMi (ropeginterferon alfa-2b) to Treat Polycythemia Vera

PharmaEssentia Appoints Sulin Shah as U.S. General Counsel, Head of Compliance

PharmaEssentia Appoints Roddy McIlwain as Senior Vice President of U.S. Sales and Marketing